Physician profile
Inna Maranets
NPI 1295713279
$665.69
in general payments reported to CMS, 2019-2025
13 companies · $161 in 2025
The $161 reported for 2025 was more than what 76% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.45 · 2020: $18.94 · 2021: $95.23 · 2022: $71.11 · 2023: $153 · 2024: $131 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $173.18 | 2023-2025 | Tremfya, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $96.03 | 2022-2024 | Gattex, Entyvio |
| Csl Behring | $74.32 | 2021-2023 | Kcentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.02 | 2022-2025 | Xifaxan |
| Celgene Corporation | $41.23 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $40.33 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $38.33 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $35.45 | 2019 | |
| Heron Therapeutics, INC. | $23.07 | 2023 | Aponvie |
| Boston Scientific Corporation | $20.21 | 2025 | General - Hemostasis |
| Baudax Bio INC. | $18.94 | 2020 | |
| Fisher & Paykel Healthcare INC | $16.35 | 2025 | Fisher & Paykel Healthcare |
| Trevena, INC. | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Maranets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.